Cite
P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
MLA
A. F. Herrera, et al. “P1087: Favezelimab (Anti–Lag-3) and Pembrolizumab Co-Blockade in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Progressed After Anti–Pd-1 Therapy: An Open-Label Phase 1/2 Study.” HemaSphere, vol. 6, June 2022, pp. 977–78. EBSCOhost, https://doi.org/10.1097/01.HS9.0000847216.85071.f3.
APA
A. F. Herrera, D. Lavie, N. A. Johnson, A. Avigdor, P. Borchmann, C. Andreadis, A. Bazargan, G. Gregory, C. Keane, T. Inna, V. Vucinic, P. L. Zinzani, H. Zhang, P. Pillai, P. Marinello, & J. Timmerman. (2022). P1087: Favezelimab (Anti–Lag-3) and Pembrolizumab Co-Blockade in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Progressed After Anti–Pd-1 Therapy: An Open-Label Phase 1/2 Study. HemaSphere, 6, 977–978. https://doi.org/10.1097/01.HS9.0000847216.85071.f3
Chicago
A. F. Herrera, D. Lavie, N. A. Johnson, A. Avigdor, P. Borchmann, C. Andreadis, A. Bazargan, et al. 2022. “P1087: Favezelimab (Anti–Lag-3) and Pembrolizumab Co-Blockade in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Progressed After Anti–Pd-1 Therapy: An Open-Label Phase 1/2 Study.” HemaSphere 6 (June): 977–78. doi:10.1097/01.HS9.0000847216.85071.f3.